Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

키워드

참고문헌 (71)

1. Younossi Z, "Global burden of NAFLD and NASH : Trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
2. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : A systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
3. Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
4. Lin S, "Comparison of MAFLD and NAFLD diagnostic criteria in real world", Liver Int, 40, pp.2082~2089 (2020)
5. Yamamura S, "MAFLD identifies patients with significant hepatic fibrosis better than NAFLD", Liver Int, 40, pp.3018~3030 (2020)
6. Kim D, "Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States", J Hepatol, 75, pp.1284~1291 (2021)
7. Huang Shang-Chin, "Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease", Gut and Liver, 15(3), pp.451~458 (2021), 거트앤리버 소화기연관학회협의회[DOI]
8. Cheng Han Ng, "Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name", Clinical and Molecular Hepatology, 28(4), pp.790~801 (2022), 대한간학회
9. Takumi Kawaguchi, "MAFLD enhances clinical practice for liver disease in the Asia-Pacific region", Clinical and Molecular Hepatology, 28(2), pp.150~163 (2022), 대한간학회[DOI]
10. Joo EJ, "Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease : A cohort study", Hepatology, 65, pp.828~835 (2017)
11. Machado MV, "Hepatic steatosis in hepatitis B virus infected patients : Meta-analysis of risk factors and comparison with hepatitis C infected patients", J Gastroenterol Hepatol, 26, pp.1361~1367 (2011)
12. Zheng Q, "Systematic review with meta-analysis : Prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B", Aliment Pharmacol Ther, 54, pp.1100~1109 (2021)
13. Jiang D, "Concurrence and impact of hepatic steatosis on chronic hepatitis B patients : A systematic review and meta-analysis", Ann Transl Med, 9, pp.1718~ (2021)
14. Pais R, "Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease", Eur J Intern Med, 26, pp.30~36 (2015)
15. Huang J, "The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease : A population-based study", J Med Virol, 92, pp.1191~1197 (2020)
16. Yu MW, "Hepatic steatosis and development of type 2 diabetes : Impact of chronic hepatitis B and viral specific factors", J Formos Med Assoc, 121, pp.1478~1487 (2022)
17. Wang MM, "Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors", Dig Dis Sci, 59, pp.2571~2579 (2014)
18. Hui RWH, "Inverse relationship between hepatic steatosis and hepatitis B viremia : Results of a large case-control study", J Viral Hepat, 25, pp.97~104 (2018)
19. Mak LY, "Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B", J Hepatol, 73, pp.800~806 (2020)
20. Hsueh RC, "Impact of PNPLA3 p. I148M and hepatic steatosis on long-term outcomes for hepatocellular carcinoma and HBsAg seroclearance in chronic hepatitis B", J Hepatocell Carcinoma, 9, pp.301~313 (2022)
21. Mao X, "Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis", Hepatology (2022)[DOI]
22. Hu D, "Nonalcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model", Hepatol Int, 12, pp.438~446 (2018)
23. Liu Q, "Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress", Mol Cell Biochem, 477, pp.2481~2491 (2022)
24. Yoon S, "Adiponectin, a downstream target gene of peroxisome proliferatoractivated receptor γ, controls hepatitis B virus replication", Virology, 409, pp.290~298 (2011)
25. Wong VW, "Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese", Am J Gastroenterol, 105, pp.132~138 (2010)
26. Seto WK, "Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B", Clin Gastroenterol Hepatol, 16, pp.575~583 (2018)
27. Choi HSJ, "Nonalcoholic steatohepatitis is associated with liverrelated outcomes and all-cause mortality in chronic hepatitis B", Hepatology, 71, pp.539~548 (2020)
28. Chan AW, "Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B", J Gastroenterol Hepatol, 32, pp.667~676 (2017)
29. Li J, "Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B", J Infect Dis, 224, pp.294~302 (2021)
30. Kanwal F, "Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease", Gastroenterology, 155, pp.1828~1837 (2018)
31. Yu MW, "Body-mass index and progression of hepatitis B : A population-based cohort study in men", J Clin Oncol, 26, pp.5576~5582 (2008)
32. Mak LY, "Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection", Hepatol Int, 15, pp.901~911 (2021)
33. Oh JH, "Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy", Hepatol Int, 15, pp.892~900 (2021)
34. van Kleef LA, "Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B", JHEP Rep, 3, pp.100350~ (2021)
35. Kim K, "Association of fasting serum glucose level and type 2 diabetes with hepatocellular carcinoma in men with chronic hepatitis B infection : A large cohort study", Eur J Cancer, 102, pp.103~113 (2018)
36. Hsu YC, "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B", J Hepatol, 69, pp.278~285 (2018)
37. Fan R, "Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy", Aliment Pharmacol Ther, 54, pp.329~338 (2021)
38. Huang SC, "Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B", J Formos Med Assoc, 121, pp.2148~2151 (2022)
39. Tapper EB, "Use of liver imaging and biopsy in clinical practice", N Engl J Med, 377, pp.756~768 (2017)
40. Middleton MS, "Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis", Gastroenterology, 153, pp.753~761 (2017)
41. Gu J, "Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease : A meta-analysis", Eur Radiol, 29, pp.3564~3573 (2019)
42. Karlas T, "Individual patient data meta-analysis of controlled attenuation parameter(CAP)technology for assessing steatosis", J Hepatol, 66, pp.1022~1030 (2017)
43. Xu L, "A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B", Dig Liver Dis, 49, pp.910~917 (2017)
44. Liang J, "A noninvasive score model for prediction of NASH in patients with chronic hepatitis B and nonalcoholic fatty liver disease", Biomed Res Int, 2017, pp.8793278~ (2017)
45. Newsome PN, "FibroScan-AST(FAST)score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis : A prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.362~373 (2020)
46. Jin X, "Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B", PLoS One, 7, pp.e34198~ (2012)
47. Chen J, "High value of controlled attenuation parameter predicts a poor antiviral response in patients with chronic hepatits B", Hepatobiliary Pancreat Dis Int, 16, pp.370~374 (2017)
48. Zhu Y, "The effect of hepatosteatosis on response to antiviral treatment in patients with chronic hepatitis B : A meta-analysis", Gastroenterol Res Pract, 2017, pp.1096406~ (2017)
49. Charatcharoenwitthaya P, "The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response", Liver Int, 37, pp.542~551 (2017)
50. Chen YC, "Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B : A retrospective study", BMC Gastroenterol, 20, pp.146~ (2020)
51. Li J, "Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients", Liver Int, 40, pp.1052~1061 (2020)
52. Hou JL, "Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24countries", Clin Gastroenterol Hepatol, 18, pp.457~467 (2020)
53. Cai J, "Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases", Circ Res, 126, pp.679~704 (2020)
54. Sun DQ, "MAFLD and risk of CKD", Metabolism, 115, pp.154433~ (2021)
55. Wang TY, "Association of metabolic dysfunction-associated fatty liver disease with kidney disease", Nat Rev Nephrol, 18, pp.259~268 (2022)
56. Allen AM, "The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity-A longitudinal cohort study", J Hepatol, 71, pp.1229~1236 (2019)
57. Younossi ZM, "AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease : Expert review", Gastroenterology, 160, pp.912~918 (2021)
58. Vilar-Gomez E, "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis", Gastroenterology, 149, pp.367~378 (2015)
59. Hashida R, "Aerobic vs. resistance exercise in non-alcoholic fatty liver disease : A systematic review", J Hepatol, 66, pp.142~152 (2017)
60. Dufour JF, "Current therapies and new developments in NASH", Gut, 71, pp.2123~2134 (2022)
61. Newsome PN, "A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
62. Francque SM, "A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH", N Engl J Med, 385, pp.1547~1558 (2021)
63. Harrison SA, "Resmetirom(MGL-3196)for the treatment of non-alcoholic steatohepatitis : A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial", Lancet, 394, pp.2012~2024 (2019)
64. Younossi ZM, "Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life", Clin Gastroenterol Hepatol, 20, pp.1354~1361 (2022)
65. Younossi ZM, "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
66. Rinella ME, "Non-invasive evaluation of response to obeticholic acid in patients with NASH : Results from the REGENERATE study", J Hepatol, 76, pp.536~548 (2022)
67. Younossi ZM, "Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis", Clin Gastroenterol Hepatol, 20, pp.2050~2058 (2022)
68. Seong Hee Kang, "From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?", Clinical and Molecular Hepatology, 27(2), pp.257~269 (2021), 대한간학회[DOI]
69. Wong GL, "Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations", Aliment Pharmacol Ther, 39, pp.883~893 (2014)
70. Chan KE, "The spectrum and impact of metabolic dysfunction in MAFLD: A longitudinal cohort analysis of 32,683 overweight and obese individuals", Clin Gastroenterol Hepatol (2022)[DOI]
71. Lee YB, "Association of metabolic risk factors with risks of cancer and all-cause mortality in patients with chronic hepatitis B", Hepatology, 73, pp.2266~2277 (2021)

관련 논문AI추천